Exactech Expands Its Computer-Assisted Surgery System With Revision Total Knee Replacement Application
October 06 2016 - 12:18PM
Business Wire
Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone
and joint restoration products for hip, knee, shoulder and spine,
today announced today the successful first U.S. surgery using the
new application of ExactechGPS® Guided Personalized Surgery system
for revision knee procedures.
According to Exactech Chief Executive Officer David Petty, “We
are pleased to broaden the use of our ExactechGPS computer guidance
system with an application for revision total knee replacement.
Even with the best implant systems in the hands of the best
surgeons, sometimes patients’ existing implants need to be removed
and replaced, due to trauma, tumors, infection or implant failure.
These ‘revision’ procedures can be challenging and complex.
Exactech is committed to developing innovations that can improve
patient outcomes for these difficult cases, and within the last 12
months we also launched three new revision implant systems,
including the Optetrak Logic® CC Comprehensive Revision Knee
System.”
To develop this technology, the company partnered with
orthopaedic surgeons, including Bernard Stulberg, MD, of St.
Vincent Charity Medical Center in Cleveland, Ohio, who was the
first to use the new ExactechGPS revision knee application last
week.
“This time last year, I had the privilege of performing the
first surgery with Exactech’s new Logic CC revision knee implant
system and now I am honored and pleased to report a successful
first surgery using the ExactechGPS revision knee application,”
said Bernard Stulberg, MD. “I am impressed with the information
this computer-assisted surgery system provided me during the case.
The revision knee application confirmed the position and alignment
of the implants, resulting in a stable and well-aligned knee. This
system has great potential to improve predictability and
reproducibility in revision total knee procedures.”
The ExactechGPS revision total knee application recently
received 510(k) clearance in the U.S., and approval in the European
Union.
The other design team members for the ExactechGPS revision knee
application include Gérard Giordano, MD, of Joseph Ducuing Hospital
in Toulouse, France, and James Huddleston, MD, of Stanford
University Medical Center.
The Exactech revision knee system is indicated for use in
skeletally mature patients undergoing surgery for total knee
replacement due to osteoarthritis, osteonecrosis, rheumatoid
arthritis and/or post-traumatic degenerative problems; this device
is also indicated for revision of failed previous reconstruction
where sufficient bone stock and soft tissue integrity are
present.
About ExactechGPS
ExactechGPS® Guided Personalized Surgery is a powerful, yet
compact advanced surgical technology platform that delivers
efficiency and reproducibility in total joint replacement. Merging
sophisticated computer guidance technology with innovative
instrumentation, ExactechGPS delivers a real-time, patient-specific
solution designed for improved clinical outcomes. For more
information about ExactechGPS®, visit www.exactechgps.com.
About Exactech
Based in Gainesville, Fla., Exactech develops and markets
orthopaedic implant devices, related surgical instruments and
biologic materials and services to hospitals and physicians. The
company manufactures many of its orthopaedic devices at its
Gainesville facility. Exactech’s orthopaedic products are used in
the restoration of bones and joints that have deteriorated as a
result of injury or diseases such as arthritis. Exactech markets
its products in the United States, in addition to more than 30
markets in Europe, Latin America, Asia and the Pacific. Additional
information about Exactech can be found
at http://www.exac.com.
*The ExactechGPS is intended for use during preoperative
planning and during stereotaxic surgery to aid the surgeon in
locating anatomical structures and aligning the endoprostheses with
the anatomical structures.
1Hopkins AR, Hansen UN, Amis AA, Emery R. The Effects of Glenoid
Component Alignment Variations on Cement Mantle Stresses in Total
Shoulder Arthroplasty. J Shoulder Elbow Surgery. 2004 Nov-Dec;
13(6):668–675.2Gregory TM, Sankey A, Augereau B, et al. Accuracy of
Glenoid Component Placement in Total Shoulder Arthroplasty and Its
Effect on Clinical and Radiological Outcome in a Retrospective,
Longitudinal, Monocentric Open Study. PLoS ONE. 2013 Oct;
8(10):e75791.
An investment profile on Exactech may be found at
http://www.hawkassociates.com/profile/exac.cfm. To receive future
releases in e-mail alerts, sign up at
http://www.hawkassociates.com/about/alert.
This release contains various forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934, which represent
the company’s expectations or beliefs concerning future events of
the company’s financial performance. These forward-looking
statements are further qualified by important factors that could
cause actual results to differ materially from those in the
forward-looking statements. These factors include the effect of
competitive pricing, the company’s dependence on the ability of
third party manufacturers to produce components on a basis which is
cost-effective to the company, market acceptance of the company’s
products and the effects of government regulation. Results actually
achieved may differ materially from expected results included in
these statements.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161006006133/en/
Investor contacts:Exactech, Inc.Jody Phillips,
352-377-1140Executive Vice President of Finance & Chief
Financial OfficerorHawk AssociatesJulie Marshall or Frank Hawkins,
305-451-1888EXAC@hawkassociates.comorMedia contact:Exactech,
Inc.Priscilla Bennett, 352-377-1140Vice President, Corporate &
Marketing Communication
Exactech, Inc. (delisted) (NASDAQ:EXAC)
Historical Stock Chart
From Aug 2024 to Sep 2024
Exactech, Inc. (delisted) (NASDAQ:EXAC)
Historical Stock Chart
From Sep 2023 to Sep 2024